Lowenthal D T, Porter R S, Saris S D, Bies C M, Slegowski M B, Staudacher A
Am J Cardiol. 1985 Oct 23;56(11):14F-18F. doi: 10.1016/0002-9149(85)90911-7.
The clinical pharmacology and pharmacodynamic data from several clinical trials are summarized. The pharmacokinetic profile of esmolol alone and in the presence of digoxin, morphine and warfarin was studied. Conversely the effect of esmolol on these drugs was monitored. No clinically important effects were observed on vital signs, blood chemistry or hematology. The pharmacokinetic interactions associated with administration of these drug combinations were statistically significant in several cases, but they were not considered to be of clinical importance.
总结了多项临床试验的临床药理学和药效学数据。研究了艾司洛尔单独使用以及与地高辛、吗啡和华法林合用时的药代动力学特征。相反，监测了艾司洛尔对这些药物的影响。在生命体征、血液化学或血液学方面未观察到具有临床重要意义的影响。在几种情况下，这些药物组合给药相关的药代动力学相互作用具有统计学意义，但它们被认为不具有临床重要性。
